The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Meta-analysis of PD-(L)1 inhibitors in Asian vs non-Asian NSCLC patients
Nicolas Girard, MD, Institut Curie, Paris, France, comments on a meta-analysis of randomized controlled studies evaluating PD-(L)1 inhibitors as monotherapy or in combination for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Outcomes were generally consistent across Asian and non-Asian populations, with both groups deriving survival benefit from first- and later-line therapy. Notably, progression-free survival appeared greater with later-line monotherapy in Asian patients. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, very nice meta-analysis of clinical trials which assessed immune checkpoint inhibitors in metastatic non-small cell lung cancer, first line and second line, and looking at the different PD-L1 subgroups of patients, including trials that enrolled Asian and non-Asian patients, trials that enrolled only Asian patients, trials with a majority of non-Asian patients. So the results are very clear...
Yeah, very nice meta-analysis of clinical trials which assessed immune checkpoint inhibitors in metastatic non-small cell lung cancer, first line and second line, and looking at the different PD-L1 subgroups of patients, including trials that enrolled Asian and non-Asian patients, trials that enrolled only Asian patients, trials with a majority of non-Asian patients. So the results are very clear. We have some level of heterogeneity in some of the comparisons, but at the end, we do not identify any difference, which is obviously something very important. At a time where we have multiple studies coming from Asia, and especially China with a very dynamic growth and new agents, new immune checkpoint inhibitors assessed in the Asian population and how to transition to the non-Asian population, well, this data makes us confident that there will be a reproducibility of the results. And for the agencies, probably it is also helpful to see that data generated in the Asian population may be applicable to the non-Asian population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
